BLACK DIAMOND THERAPEUTICS, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $185.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $185.00K.
- BLACK DIAMOND THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-06-30 was $142.00K, a 468.00% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2024-06-30 was $25.00K.
- BLACK DIAMOND THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $400.00K, a 1500.00% increase from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $25.00K, a 45.65% decline from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $46.00K, a 64.29% increase from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $28.00K.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|
| 2026-03-31 | $185.00K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $400.00K 10-K · filed 2026-03-16 | |
| 2025-06-30 | $142.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $25.00K 10-K · filed 2026-03-16 | |
| 2024-06-30 | $25.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $46.00K 10-K · filed 2025-03-06 | |
| 2022-12-31 | $28.00K 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |